NEGATIVE EFFECTS OF VITAL DYES AFTER UNEVENTFUL VITREOMACULAR SURGERYRöhrig, Stephan, MD*; Farecki, Marie-Louise, MD†; Boden, Karl T., MD*; Haus, Arno, MD*; Gutfleisch, Matthias, MD†; Jung, Sascha, PhD; Lommatzsch, Albrecht, MD†; Szurman, Peter, MD*; Januschowski, Kai, MD*RETINA: June 27, 2018 - Volume Publish Ahead of Print - Issue - p doi: 10.1097/IAE.0000000000002231 Original Study: PDF Only Buy PAP Abstract In Brief Author InformationAuthors Article MetricsMetrics Purpose: Vital dyes have become a clinical standard during chromovitrectomy but toxicity remains an issue. We compared the clinical outcome of one supposedly toxic vital dye (AV 17 with 5% mannitol) with a standard vital dye (MBB Dual) and performed a power analysis for future comparative studies. Methods: Retrospective analysis of 270 eyes after chromovitrectomy with internal limiting membrane peeling because of macular holes. Primary endpoint was loss in BCVA >2 lines and photoreceptor atrophy as seen on optical coherence tomography examination. Results: In 173 eyes, staining of the epiretinal membrane and extracellular matrix was performed using MBB (Group A), and in 97 using AV 17-M (Group B). The mean BCVA was not significantly different after more than 3 months and also not in the early postoperative period after surgery between Group A and Group B. The number of patients suffering from a decline in BCVA of two lines and more was not significantly higher in patients of Group B. There was not a significantly higher percentage of patients with an inner segment/outer segment defect. Conclusion: Our rather homogeneous study showed no significant difference between both dyes. Thousand five hundred patients would need to be examined to find a significant difference in future studies. The aim of this retrospective study was to investigate negative effects of two vital dyes (AV 17 with 5% mannitol and MBB Dual) after surgery. Because of the results, it is advisable to perform postmarketing analysis to increase patient safety. *Eye Hospital Sulzbach, Sulzbach/Saar, Germany; and †St Franziskus Eye Hospital Münster, Münster, Germany. Reprint requests: Stephan Röhrig, MD, Eye Clinic Sulzbach/Saar, An der Klinik 10, Sulzbach 66111, Saar, Germany; e-mail: email@example.com None of the authors has any financial/conflicting interests to disclose. © 2019 by Ophthalmic Communications Society, Inc.